Literature DB >> 7568625

The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats.

I Nylander1, M Vlaskovska, L Terenius.   

Abstract

The effect of morphine tolerance and withdrawal on prodynorphin peptides was studied in relevant brain areas and in the pituitary gland of male Sprague-Dawley rats, and compared with effects on the proenkephalin-derived peptide Met-enkephalin. After 8 days of morphine injections (twice daily), dynorphin A and B levels increased in the nucleus accumbens and dynorphin A levels increased also in the striatum. Morphine treatment increased striatal Met-enkephalin. Leu-enkephalinArg6 levels were reduced in the ventral tegmental area (VTA). Morphine-treated rats had very low Leu-enkephalinArg6 levels in the hippocampus as compared to saline control rats. Comparison of the relative amounts of dynorphin peptides and the shorter prodynorphin-derived peptides, Leu-enkephalinArg6 and Leu-enkephalin, revealed a relative increase in dynorphin peptides versus shorter fragments in the nucleus accumbens, VTA and hippocampus. Morphine-tolerant rats had lower levels of dynorphin A in both lobes of the pituitary gland, whereas hypothalamic dynorphin levels were unaffected by morphine. Leu-enkephalinArg6 levels were reduced in the hypothalamus, but not changed in the pituitary gland. Naloxone-precipitated withdrawal accentuated the increase in dynorphin A and B levels in the accumbens and dynorphin A levels in the striatum, while inducing an increase in enkephalin levels in the accumbens and Met-enkephalin in the VTA. In the hippocampus, Leu-enkephalinArg6 levels remained low in the withdrawal state. The low dynorphin levels in the anterior part of the pituitary gland were reversed by naloxone, whereas the low dynorphin A levels in the neurointermediate lobe were 0ven lower in the withdrawal state.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568625     DOI: 10.1007/BF02245939

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  61 in total

1.  Levels of dynorphin peptides, substance P and CGRP in the spinal cord after subchronic administration of morphine in the rat.

Authors:  I Nylander; T Sakurada; P Le Greves; L Terenius
Journal:  Neuropharmacology       Date:  1991-11       Impact factor: 5.250

2.  Changes in prodynorphin peptide content following treatment with morphine or amphetamine: possible role in mechanisms of action of drug of abuse.

Authors:  K A Trujillo; H Akil
Journal:  NIDA Res Monogr       Date:  1989

3.  Relative contents and concomitant release of prodynorphin/neoendorphin-derived peptides in rat hippocampus.

Authors:  C Chavkin; C Bakhit; E Weber; F E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

4.  A general procedure for analysis of proenkephalin B derived opioid peptides.

Authors:  I Christensson-Nylander; F Nyberg; U Ragnarsson; L Terenius
Journal:  Regul Pept       Date:  1985-05

5.  Chronic administration of morphine decreases level of dynorphin A in the rat nucleus accumbens.

Authors:  Q Z Zhai; S Persson; C Post; F Nyberg
Journal:  Neuropharmacology       Date:  1993-07       Impact factor: 5.250

6.  Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.

Authors:  T M Engber; R C Boldry; S Kuo; T N Chase
Journal:  Brain Res       Date:  1992-05-29       Impact factor: 3.252

7.  Morphine alters preproenkephalin gene expression.

Authors:  G R Uhl; J P Ryan; J P Schwartz
Journal:  Brain Res       Date:  1988-09-06       Impact factor: 3.252

8.  Blockade of morphine-induced analgesia and tolerance in mice by MK-801.

Authors:  K Lutfy; D E Hurlbut; E Weber
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

9.  Self-administration of dynorphin-[1-13] and D-ala2-dynorphin-[1-11] (kappa opioid agonists) in morphine (mu opioid agonist)-dependent rats.

Authors:  N Khazan; G A Young; D Calligaro
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

10.  Enkephalin: radioimmunoassay and radioreceptor assay in morphine dependent rats.

Authors:  S R Childers; R Simantov; S H Snyder
Journal:  Eur J Pharmacol       Date:  1977-12-01       Impact factor: 4.432

View more
  17 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Protracted manifestations of acute dependence after a single morphine exposure.

Authors:  Patrick E Rothwell; Mark J Thomas; Jonathan C Gewirtz
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

Review 3.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

4.  The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal.

Authors:  Angelo Contarino; Francesco Papaleo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

5.  Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys.

Authors:  S Stevens Negus; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

6.  Different affective response to opioid withdrawal in adolescent and adult mice.

Authors:  Stephen R Hodgson; Rebecca S Hofford; Paul J Wellman; Shoshana Eitan
Journal:  Life Sci       Date:  2008-11-12       Impact factor: 5.037

Review 7.  Dynorphin and its role in alcohol use disorder.

Authors:  Anushree N Karkhanis; Ream Al-Hasani
Journal:  Brain Res       Date:  2020-02-28       Impact factor: 3.252

8.  Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.

Authors:  L Lalanne; G Ayranci; D Filliol; C Gavériaux-Ruff; K Befort; B L Kieffer; P-E Lutz
Journal:  Addict Biol       Date:  2016-03-22       Impact factor: 4.280

9.  Hippocampal dynorphin immunoreactivity increases in response to gonadal steroids and is positioned for direct modulation by ovarian steroid receptors.

Authors:  A Torres-Reveron; S Khalid; T J Williams; E M Waters; L Jacome; V N Luine; C T Drake; B S McEwen; T A Milner
Journal:  Neuroscience       Date:  2008-12-24       Impact factor: 3.590

10.  Long-term antagonism of κ opioid receptors prevents escalation of and increased motivation for heroin intake.

Authors:  Joel E Schlosburg; Timothy W Whitfield; Paula E Park; Elena F Crawford; Olivier George; Leandro F Vendruscolo; George F Koob
Journal:  J Neurosci       Date:  2013-12-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.